Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Clinical Trial

Official title:

Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05842707
• Other study ID #: 2023-008
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 18, 2023
• Est. completion date: January 18, 2029

Study information

• Verified date: April 2023
• Source: Shanghai Tongji Hospital, Tongji University School of Medicine
• Contact: aibin Liang
• Phone: 18601670600
• Email: lab7182[@]tongji.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To find the highest tolerable dose of dualCAR-NK19/70 (a type of cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.

Description:

Primary Objectives:

--The primary objective is to determine the safety and identify the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of dualCAR-NK19/70 in patients with r/r B-cell lymphomas.

Hypothesis: DualCAR-NK19/70 will be safe, well-tolerated, and effective in patients with r/r B-cell lymphomas.

Secondary Objectives:

--The secondary objective is to determine the efficacy in adults with r/r LBCL and FL grade 3B treated at the MTD or RP2D of dualCAR-NK19/70. Although the clinical benefit of dualCAR-NK19/70 has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit, and thus the patient will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability. Secondary endpoints include overall response rate (ORR; including CR + PR) and CR rate as defined by the Lugano Classification response criteria for malignant lymphoma, DOR, PFS, and OS.

Exploratory Objectives:

--The exploratory objectives are to assess the cellular kinetics and pharmacodynamic effects of dualCAR-NK19/70 and to evaluate biomarkers associated with response, resistance, and toxicity after administration of dualCAR-NK19/70 in blood and tumor samples.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: January 18, 2029
• Est. primary completion date: January 18, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Voluntarily participate in the study and sign the informed consent;

2. Age 18-75, male and female;

3. Histologically confirmed diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), primary mediastinal B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL), and other Indolent B-cell NHL transforming types:

(A) Relapsed or Refractory DLBCL and tFL after 2 lines Immunotherapy or chemotherapy ; (B) Definition of Refractory large B cell lymphoma (SCHOLAR - 1 Research Standard) : disease progression after more than 4 courses of standard Immunotherapy or chemotherapy; Or the time of disease stabilization = 6 months; Or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation (auto-HSCT); (C) Relapsed or Refractory MCL must be 1 line with immune chemotherapy; BTK inhibitors are resistant or intolerant as 2-line therapy; (D) Relapsed or Refractory disease after chemotherapy including rituximab and anthracycline.

4. There was at least one measurable lesion with the longest diameter = 1.5cm;

5. Estimated life expectancy of more than 12 weeks other than primary disease;

6. Previously confirmed diagnosis as CD19+ or CD70+ B-NHL.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3.

8. Adequate reserve of organ function:

(A) Serum alanine aminotransferase (ALT) / aspartate aminotransferase (AST) =2.5 times the Upper Limit of Normal (ULN) for age; (B) A creatinine clearance (as estimated either by a direct urine collection or Cockcroft-Gault Equation) > 60mL/min; (C) Total bilirubin and alkaline phosphatase =1.5 times the Upper Limit of Normal (ULN) for age; (D) glomerular filtration rate > 50 ml/min (E) Cardiac ejection fraction (EF) = 45% as determined by an echocardiogram (ECHO) or Multigated Radionuclide Angiography (MUGA); (F) Baseline oxygen saturation >92% on room air (G) Absolute neutrophil count > 1000/µL, Platelet count > 45,000/µL ,Hemoglobin > 80g/L;

9. Once previous autologous hematopoietic stem cell transplantation (auto-HSCT) is allowed;

10. For systemic therapy(Such as systemic chemotherapy, systemic radiotherapy and immunotherapy), at least 3 weeks,for Targeted drug therapy alone,at least 2 weeks,must have elapsed at the time of cell infusion;

11. Either having failed or Relapsed after CAR-T therapy at 3 months of assessment;

12. Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until the follow-up period of the study. Women of childbearing potential must have a negative serum or urine pregnancy test.

13. The viral load of severe coronavirus disease 2019 (COVID-19) is undetectable per quantitative PCR and/or nucleic acid testing for two tests.

Exclusion Criteria:

1. Allergic to any of the components of cell products;

2. Previous or concurrent of other type of maligant tumors;

3. Acute GvHD or generalized chronic GvHD with grade II-IV (Glucksberg standard) after previous autologous hematopoietic stem cell transplantation (auto-HSCT); Or receiving of anti-GVHD therapy;

4. Known history of systemic gene therapy within the prior 3 months;

5. Active systemic fungal, viral, or bacterial infection (except for simple urinary tract infections and bacterial pharyngitis), however, Preventive treatment is permitted;

6. Known history of infection with hepatitis B (HBsAg positive, but HBV-DNA<1000 is not excluded) or hepatitis C virus (including virus carriers), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to HIV infection;

7. Class III or IV heart failure as defined by the New York Heart Association;

8. Persisting toxicities (>grade 1, except for clinically non-significant toxicities such as alopecia, fatigue, and anorexia) due to prior trerapy;

9. Known history of active seizures or presence of seizure activities or other central nervous system disease;

10. Have evidence of central nervous system lymphoma(CNS lymphoma) on CT or MRI;

11. Breast-feeding woman;

12. Any circumstances that possibly increase the risk of subjects or interfere with study results, which judged by investigator.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Non-Hodgkin
• Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

Intervention

Drug:
• dualCAR-NK19/70 cell
Given by IV (vein)

Locations

Country	Name	City	State
China	Shanghai Tongji Hospital, Tongji University School of Medicine	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Aibin Liang,MD,Ph.D.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of Adverse Events	Type, frequency, and severity of adverse events,Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5	through study completion; an average of 1 year,up to 3 years
Other	Exploratory Objectives	The exploratory objectives are to assess the cellular kinetics and pharmacodynamic effects of dualCAR-NK19/70 and to evaluate biomarkers associated with response, resistance, and toxicity after administration of dualCAR-NK19/70 in blood and tumor samples.	Up to 3 years
Primary	incidence of dose limiting toxicity(DLTs)	To evaluate the safety,tolerabitility,and determine the recommended dosage of cord blood-derived CAR NK cells targeting CD19/CD70	up to 28 days
Secondary	Objective Response Rate(ORR)	To determine the anti-tumor effectivity of CB dualCAR-NK19/70	6 months
Secondary	Complete Remission Rate(CRR)	To determine the anti-tumor effectivity of CB dualCAR-NK19/70	3 months
Secondary	Overall survival(OS)	To determine the anti-tumor effectivity of CB dualCAR-NK19/70	Up to 3 years
Secondary	Duration of Response(DOR)	To determine the anti-tumor effectivity of CB dualCAR-NK19/70	Up to 3 years
Secondary	progression-free survival(PFS)	To determine the anti-tumor effectivity of CB dualCAR-NK19/70	Up to 3 years